Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.
about
Morphoproteomic confirmation of an activated nuclear factor-кBp65 pathway in follicular thyroid carcinomaProteomics, morphoproteomics, saliva and breast cancer: an emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response.Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.Data driven linear algebraic methods for analysis of molecular pathways: application to disease progression in shock/trauma.Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogAlveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.Analysis of NF-kappaB signaling pathways by proteomic approaches.Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants.Morphoproteomics, E6/E7 in-situ hybridization, and biomedical analytics define the etiopathogenesis of HPV-associated oropharyngeal carcinoma and provide targeted therapeutic options.Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.Clear cell sarcoma of kidney: morphoproteomic analysis reveals genomic correlates and therapeutic options.Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma.Preliminary experience with personalized and targeted therapy for pediatric brain tumors.Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.Carcinosarcoma of the parotid: investigating its biology with morphoproteomics.
P2860
Q24630133-BB42DA2F-979B-41D4-8132-0A543ABE7106Q33694698-D8E4E42F-3B9B-4718-A1AE-91BB8C0AF081Q33873775-5F401FA1-FBBC-49CB-AF24-AC8099725483Q34112355-5D8F4163-CBEA-453B-97AA-BC76C5BBAE25Q34566745-30808B07-37B4-4672-BA9F-BC679FE733F8Q36196768-5C5E4CA8-E8AC-4A34-A4E0-B9A67E823CEFQ36375393-88CD4409-E7CF-45D4-92A2-39E477B898A0Q36392814-4D2D5951-9947-4170-8FBA-493335E0A4DDQ36784882-229118E2-5A6D-41C0-919B-9FBE35DC92A9Q37009828-979AAB0D-0CA1-4881-AFC7-9CF78328FC9FQ37520310-7FF12F18-C2AB-48E8-81D4-1FCD74276F55Q37564708-D0A19987-A72B-4B1E-884F-A34B81050D0DQ37727184-32FE1FF9-648D-4F84-9E7E-8407030C28D6Q38408932-B3D4BBA2-2F66-4DB1-B078-A617B1D5F672Q38619611-2A263E53-BA03-4EE2-882F-C3E2874BE143Q39868627-CBDAA074-E57E-4B7D-BB70-0953A7742958Q41582917-36D8E129-FB1E-4FAF-A889-1DFAEE839E84Q42070616-EAC1EB29-D76B-485D-9B55-C8658AE627BAQ46311312-192CF860-C9B7-4889-A6D3-4346E556309EQ48675160-290C4E50-92E9-477D-A740-F10FE10ED14BQ48785864-D9A61CDD-18C7-4305-923F-24D511E4C37FQ53323040-9CA1DEED-306E-4530-B14D-8A04E6FB2FEFQ53666843-6A1F7E58-A90E-43A2-8764-F6804E23635E
P2860
Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@ast
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@en
type
label
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@ast
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@en
prefLabel
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@ast
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@en
P2860
P356
P1476
Morphoproteomics: exposing pro ...... ic targets in cancer patients.
@en
P2093
Robert E Brown
P2860
P304
P356
10.1586/14789450.2.3.337
P577
2005-06-01T00:00:00Z